Synergism of Adipocytokine Profile and
Adiponectin
/ genetics
Adult
Alleles
Colorectal Neoplasms
/ genetics
Female
Humans
Liver Neoplasms
/ genetics
Male
Middle Aged
Neoplasm Metastasis
Neoplasm Proteins
/ genetics
Non-alcoholic Fatty Liver Disease
/ genetics
Obesity
/ genetics
Polymorphism, Genetic
Tumor Necrosis Factor-alpha
/ genetics
Adiponectin
NAFLD
TNF-α
colorectal cancer
leptin
metabolic syndrome
obesity
Journal
Cancer genomics & proteomics
ISSN: 1790-6245
Titre abrégé: Cancer Genomics Proteomics
Pays: Greece
ID NLM: 101188791
Informations de publication
Date de publication:
Historique:
received:
05
08
2019
revised:
20
08
2019
accepted:
21
08
2019
entrez:
30
10
2019
pubmed:
30
10
2019
medline:
12
3
2020
Statut:
ppublish
Résumé
The aim of this study was to evaluate whether the altered profile of adipocytokine and genetic fingerprint in NAFLD-associated metabolic syndrome "cluster" represents synergistic risk factors predicting onset of liver colorectal cancer metastases. A total of 165 colorectal cancer patients were enrolled, 56,3% were with metabolic syndrome/NAFLD. Serum samples were assayed for ADIPOQ, leptin and TNF-a levels by ELISA. ADIPOQ rs266729 C/G and TNF-308 A/G genotypes were analyzed in DNA isolated from whole blood. Reduction in adiponectin levels and increase in leptin and TNF-α was shown in patients with liver metastases. This trend was influenced by BMI, MetS/NAFLD, and insulin resistance. ADIPOQ G rs266729 and TNF- 308 A allele are associated with obesity, MetS/NAFLD and insulin resistance. ADIPOQ CG/GG and GA/AA TNF-alpha genotypes confer susceptibility to liver metastases. Obesity and hepatic steatosis significantly favor the development of colorectal cancer liver metastases and the individual adipocytokines genetic profile may play an important predictive role.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
The aim of this study was to evaluate whether the altered profile of adipocytokine and genetic fingerprint in NAFLD-associated metabolic syndrome "cluster" represents synergistic risk factors predicting onset of liver colorectal cancer metastases.
MATERIALS AND METHODS
METHODS
A total of 165 colorectal cancer patients were enrolled, 56,3% were with metabolic syndrome/NAFLD. Serum samples were assayed for ADIPOQ, leptin and TNF-a levels by ELISA. ADIPOQ rs266729 C/G and TNF-308 A/G genotypes were analyzed in DNA isolated from whole blood.
RESULTS
RESULTS
Reduction in adiponectin levels and increase in leptin and TNF-α was shown in patients with liver metastases. This trend was influenced by BMI, MetS/NAFLD, and insulin resistance. ADIPOQ G rs266729 and TNF- 308 A allele are associated with obesity, MetS/NAFLD and insulin resistance. ADIPOQ CG/GG and GA/AA TNF-alpha genotypes confer susceptibility to liver metastases.
CONCLUSION
CONCLUSIONS
Obesity and hepatic steatosis significantly favor the development of colorectal cancer liver metastases and the individual adipocytokines genetic profile may play an important predictive role.
Identifiants
pubmed: 31659105
pii: 16/6/519
doi: 10.21873/cgp.20154
pmc: PMC6885361
doi:
Substances chimiques
ADIPOQ protein, human
0
Adiponectin
0
Neoplasm Proteins
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
519-530Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
J Clin Endocrinol Metab. 2018 Mar 1;103(3):1015-1023
pubmed: 29325128
Clin Liver Dis. 2018 Feb;22(1):11-21
pubmed: 29128051
Dig Dis Sci. 2017 Sep;62(9):2511-2517
pubmed: 28733869
Minerva Gastroenterol Dietol. 2018 Mar;64(1):39-50
pubmed: 28875689
Int J Mol Sci. 2017 Jul 29;18(8):
pubmed: 28758929
Compr Physiol. 2017 Dec 12;8(1):237-282
pubmed: 29357128
Aliment Pharmacol Ther. 2017 Jan;45(2):345-353
pubmed: 27859470
Curr Ther Res Clin Exp. 2014 Sep 27;76:70-5
pubmed: 25352937
Int J Biol Sci. 2019 Jan 1;15(3):610-616
pubmed: 30745847
Obes Rev. 2005 Feb;6(1):13-21
pubmed: 15655035
Hippokratia. 2016 Oct-Dec;20(4):259-263
pubmed: 29416297
Kardiologiia. 2015 Sep;55(9):25-30
pubmed: 28294921
Contemp Oncol (Pozn). 2019;23(2):63-68
pubmed: 31316286
Iran J Basic Med Sci. 2015 May;18(5):430-42
pubmed: 26124928
J Cancer. 2017 Mar 25;8(6):1000-1008
pubmed: 28529612
J Gastrointest Surg. 2019 Nov;23(11):2298-2306
pubmed: 31270721
Int J Cancer. 2018 Aug 1;143(3):543-551
pubmed: 29488210
Nat Rev Endocrinol. 2019 Mar;15(3):139-154
pubmed: 30459447
Adv Nutr. 2018 Jan 1;9(1):30-40
pubmed: 29438460
Clin Liver Dis. 2016 May;20(2):245-62
pubmed: 27063267
Diabetes Metab Syndr. 2017 Dec;11 Suppl 2:S867-S871
pubmed: 28711516
Nutr Res. 2017 Sep;45:63-72
pubmed: 28967457
Int J Mol Sci. 2014 Apr 11;15(4):6184-223
pubmed: 24733068
Diabetologia. 2016 Jan;59(1):30-43
pubmed: 26407715
PLoS One. 2015 Jun 04;10(6):e0127521
pubmed: 26042596
Eur J Cancer. 2011 Nov;47(17):2560-7
pubmed: 21803570
Int J Mol Sci. 2019 May 22;20(10):
pubmed: 31121868
Metabolism. 2016 Aug;65(8):1038-48
pubmed: 26823198
Asia Pac J Clin Nutr. 2014;23(1):167-73
pubmed: 24561985
Obes Res. 2005 Dec;13(12):2122-31
pubmed: 16421346
Child Obes. 2016 Aug;12(4):300-13
pubmed: 27159547
Metabolism. 2016 Aug;65(8):1062-79
pubmed: 26725002
Cell Oncol (Dordr). 2019 Jun;42(3):243-260
pubmed: 30877623
Clin Mol Hepatol. 2018 Dec;24(4):392-401
pubmed: 30068065
Endocrine. 2014 Aug;46(3):435-44
pubmed: 24515539
Clin Chim Acta. 2013 Feb 18;417:80-4
pubmed: 23266767
Diabetes Metab Res Rev. 2018 Nov;34(8):e3050
pubmed: 30052309
Best Pract Res Clin Gastroenterol. 2014 Aug;28(4):637-53
pubmed: 25194181
Br J Cancer. 2016 Jun 28;115(1):34-9
pubmed: 27280634
Obes Rev. 2013 Mar;14(3):232-44
pubmed: 23171381
Fertil Steril. 2017 Apr;107(4):833-839
pubmed: 28292617
J Endocrinol. 2019 Jun 1;241(3):R81-R96
pubmed: 30959481
J Hepatol. 2017 Oct;67(4):829-846
pubmed: 28545937
Best Pract Res Clin Endocrinol Metab. 2014 Jan;28(1):107-17
pubmed: 24417950
Cytokine. 2019 Sep;121:154735
pubmed: 31154250
J Assist Reprod Genet. 2015 Apr;32(4):625-34
pubmed: 25690158
J Endocrinol. 2014 Jan 08;220(2):T47-59
pubmed: 24403378
Chin J Cancer Res. 2016 Oct;28(5):536-542
pubmed: 27877013
Mol Cell Biochem. 2012 Jan;360(1-2):1-7
pubmed: 22081334
J Cardiovasc Pharmacol Ther. 2017 Jul;22(4):365-367
pubmed: 28587579
Mymensingh Med J. 2015 Oct;24(4):873-80
pubmed: 26620035